Lopinavir/ritonavir en nuevas estrategias de simplificación del tratamiento antirretroviral. [artículo]
Por: Lagarde Sebastián, María de [Medicina Interna]
| Bisbal Pardo, Otilia [Medicina Interna] | Pulido Ortega, Federico [Unidad VIH].
Colaborador(es): Servicio de Medicina Interna.
Tipo de material: 
ArtículoEditor: Enfermedades infecciosas y microbiología clínica, 2014Descripción: 32 Suppl 3:12-7.Recursos en línea: Solicitar documento Resumen: Interest in simplification arises from the need to dispense with nucleoside analogs due to their long-term toxicity. Since the first trials analyzing the safety and effectiveness of the strategy with lopinavir/ritonavir (LPV/r) emerged more than 10 years ago, simplification continues to arouse scientific, clinical and economic interest. At present, there is no consensus on recommendations; interpretations of results are discordant: while some emphasize the greater risk of loss of virologic control, others indicate that the possible virological rebound with this strategy is unrelated to a loss of therapeutic options or to the emergence of resistance to ritonavir-boosted protease inhibitors. This scenario governs the recommendations that can be made in clinical practice; almost all groups agree that candidates should be selected for a simplification strategy with fewer drugs.
| Tipo de ítem | Ubicación actual | Signatura | Estado | Fecha de vencimiento |
|---|---|---|---|---|
Artículo
|
PC16393 (Navegar estantería) | Disponible |
Formato Van couver:
Sebastián Mde L, Pardo OB, Ortega FP. Lopinavir/ritonavir en nuevas estrategias de simplificación del tratamiento antirretroviral. Enferm Infecc Microbiol Clin. 2014 Nov;32 Suppl 3:12-7.
PMID: 25542870
Contiene 24 referencias
Interest in simplification arises from the need to dispense with nucleoside analogs due to their long-term toxicity. Since the first trials analyzing the safety and effectiveness of the strategy with lopinavir/ritonavir (LPV/r) emerged more than 10 years ago, simplification continues to arouse scientific, clinical and economic interest. At present, there is no consensus on recommendations; interpretations of results are discordant: while some emphasize the greater risk of loss of virologic control, others indicate that the possible virological rebound with this strategy is unrelated to a loss of therapeutic options or to the emergence of resistance to ritonavir-boosted protease inhibitors. This scenario governs the recommendations that can be made in clinical practice; almost all groups agree that candidates should be selected for a simplification strategy with fewer drugs.
No hay comentarios para este ejemplar.